Neoadjuvant Chemotherapy and Surgical Treatment in Advanced Stages of Non-Small Cell Lung Cancer
Authors:
M. Szkorupa; J. Klein 1; T. Bohanes; Č. Neoral; V. Kolek 2; I. Grygárková 2
Authors‘ workplace:
I. chirurgická klinika FN a LF UP Olomouc, přednosta: doc. MUDr. Č. Neoral, CSc.
; Krajská nemocnice T. Bati, a. s., Zlín, primář: prof. MUDr. J. Klein, Ph. D.
1; Klinika plicních nemocí a tuberkulózy FN a LF UP Olomouc, přednosta: prof. MUDr. V. Kolek, DrSc.
2
Published in:
Rozhl. Chir., 2011, roč. 90, č. 8, s. 433-439.
Category:
Monothematic special - Original
Overview
Introduction:
Lung cancer takes first place in both incidence and mortality in the Czech Republic. This is associated with the disease being diagnosed in late stages, which limits the possibility of radical therapy. Five-year survival of patients operated on with stage IIIA is low and doesn’t even reach 20%. These poor results and the development of systemic chemotherapy in the 1990’s led to an effort to treat locally advanced disease by administering chemotherapy before the surgical procedure- induction chemotherapy. Its benefit, however, unlike that of adjuvant chemotherapy, remains unclear.
Aim:
To analyze and compare the results between a set of patients with non-small cell lung cancer (NSCLC) with stage III A-B, operated on at the I. Department of Surgery at the University Hospital and Palacky Medical Faculty in Olomouc between the years 2000–2008, who underwent preoperative chemotherapy with the results of patients with stage III A-B diagnosed after the operation based on histological findings. Three- and five-year survivals, as well as survival median, were evaluated in both groups.
Results:
A statistically significant difference in survival between the two groups was not observed.
Conclusion:
Neoadjuvant chemotherapy remains controversial in the treatment of NSCLC. The initially promising results have not been unequivocally confirmed in later studies and its role remains a question to be answered in future extensive randomized studies.
Key words:
non-small cell lung cancer – surgical treatment – preoperative chemotherapy
Sources
1. ÚZIS ČR, Aktuální informace č. 6/2009.
2. Skřičková, J., Čoupek, P., Babičková, L., et al. Léčebné postupy u nemalobuněčného karcinomu plic. Klinická onkologie, 2008; 21: 317–329.
3. Kolek, V., Grygárková, I., Hajdúch, M. Long term follow-up of neoadjuvant-adjuvant combination treatment of IIIA stage non-small-cell-lung cancer: results of neoadjuvant carboplatin/vinorelbine and carboplatin/paclitaxel regiment combined with selective adjuvant chemotherapy according to in-vitro chemoresistance test. Biomed. Pap. Med. Fac. Univ. Palacky Olomouc Czech Repub., 2008; 152(2): 259–266.
4. Klein, J. Chirurgie karcinomu plic. Praha, Grada publishing, a.s., 2006.
5. Špásová, I. Postavení neoadjuvantní chemoterapie v léčbě nemalobuněčného plicního karcinomu. Vnitřní lékařství, 2007; 53(6): 715–723.
6. Mountain, C. F. Revisions in the international system for staging lung cancer. Chest, 1997; 111: 1710–1717.
7. van Schil, P. E., de Waele, M., Hendricks, J. M., Lauwers, P. R. Surgical treatment of stage III non-small cell lung cancer. European Journal of Cancer, 2009; 45: 106–112.
8. Carretta, A., Ciriaco, P., Melloni, G., et al. Results of surgical treatment after neodajuvant chemotherapy for stage III non-small cell lung cancer. World J. Surg., 2008; 32: 2636–2642.
9. Gray, J., Sommers, E., Alvelo-Rivera, M., et al. Neoadjuvant chemotherapy of resectable non-small-cell lung cancer. Oncology, 2009; 23(10): 879–886.
10. De Marinis, F., Tedesco, B., Treggiari, S., et al. Role of induction chemotherapy in resectable N2 non-small cell lung cancer. J. Thorac. Oncol., 2007; 2(5): 31–34.
11. Rosell, R., Gomez-Codina, J., Camps, C., et al. A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer. N. Engl. J. Med., 1994; 330(3): 153–158.
12. Roth, J. A., Fossella, F., Komaki, R., et al. A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer. J. Natl. Cancer Inst., 1994; 86: 673–680.
13. Depierre, A., Milleron, B., Moro-Sibilot, D., et al. Preoperative chemotherapy followed by surgery compared with primary surgery in resectable stage I (except T1N0), II and IIIa non-small-cell lung cancer. J. Clin. Oncol., 2002; 20: 247–253.
14. De Marinis, F., Gebbia, V., De Petris, L. Neoadjuvant chemotherapy for stage IIIA – N2 non small cell lung cancer. Ann. Oncol., 2005; 16(4): 116–122.
15. Stinchcombe, T. E., Socinski, M. A. The Role of induction therapy for resectable non-small cell lung cancer. Drugs, 2007; 67(3): 321–333.
16. S9900: Surgery alone or surgery plus induction (ind) paclitaxel/carboplatin (PC) chemotherapy in early stage non-small cell lung cancer (NSCLC): Follow-up on a phase III trial. Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18S (June 20 Supplement), 2007: 7520.
17. NATCH Trial Finds No Benefit When Chemo is Added to Surgery in Early-Stage Lung Cancer – 13th World Conference on Lung Cancer (WCLC) July 31 – August 4, 2009; San Francisco, California.
18. Kolek, V., Grygárková, I., Hajdúch, M. Neoadjuvantní chemoterapie u hraničně operabilních stadií IIIA nemalobuněčného karcinomu plic kombinací vinorelbin a karboplatina. Následná cílená adjuvantní chemoterapie. Klinická onkologie 2001; 14: 55–58.
19. Bueno, R., Richards, W. G., Swanson, S. J., et al. Nodal stage after induction therapy for stage IIIA lung cancer determines patient survival. Ann. Thorac. Surg., 2000; 70: 1826–1831.
20. Voltolini, L., Luzzi, L., Ghiribelli, C., et al. Results of induction chemotherapy followed by surgical resection in patients with stage IIIA (N2) non-small cell lung cancer: the importance of the nodal down-staging after chemotherapy. Eur. J. Cardiothorac. Surg., 2001; 20: 1106–1112.
21. Detterbeck, F. C., Socinski, M. A. Induction therapy and surgery for stage IIIIA, B non-small lung cancer. In: Detterbeck, F. C., Socinski, M. A., Rivera, M. et al.: Diagnosis and treatment of lung cancer. W. B. Saunders Comp., 2001: 267–282.
22. van Schil, P., van der Schoot, J., Poniewierski, J., et al. Remediastinoscopy after neoadjuvant therapy for non-small cell lung cancer. Lung Cancer, 2002; 37: 281–285.
23. Mateu-Navarro, M., Rami-Porta, R., Bastus-Piulats, R., et al. Remediastinoscopy after induction chemotherapy in non-small cell lung cancer. Ann. Thorac. Surg., 2000; 70: 391–395.
24. Lardinois, D. Pre- and intra-operative mediastinal staging in non-small-cell lung cancer. Swiss Med. Wkly., 2011 Mar 8;141:w13168. doi: 10.4414/smw.2011.13168.
25. Mansour, Z., Kochetkova, E. A., Ducrocq, X., et al. Induction chemotherapy does not increase the operative risk of pneumonectomy! Eur. J. Cardiothorac. Surg., 2007; 31: 181–185.
26. Martin, J., Ginsberg, R. J., Abolhoda, A., et al. Morbidity and mortality after neoadjuvant therapy for lung cancer: The risks of right pneumonectomy. Ann. Thorac. Surg., 2001; 72: 1149–1154.
27. Pisters, K. M., Ginsberg, R. J., Giroux, D. J., et al. Bimodality Lung Oncology Team. Induction chemotherapy before surgery for early-stage lung cancer: a novel approach. J. Thorac. Cardiovasc. Surg., 2000; 119: 429–439.
28. Cerfolio, R. J., Bryant, A. S., Jones, V. L., Cerfolio, R. M. Pulmonary resection after concurrent chemotherapy and high dose (60Gy) radiation for non small cell lung cancer is safe and may provide increased survival. Eur. J. Cardiothorac. Surg., 2009; 35: 718–723.
Labels
Surgery Orthopaedics Trauma surgeryArticle was published in
Perspectives in Surgery
2011 Issue 8
Most read in this issue
- Pilonidal Sinus – A Classical Plastic Procedure according to Limberg (Limberg Flap Procedure) or Its Modified Version?
- Diverticular Disease of Colon
- Non-tumor Bile Duct Strictures
- Biochemic Evidence of the Presence of Urine in a Drain Following Surgery